Open AccessA Model of BMD Changes After Alendronate Discontinuation to Guide Postalendronate BMD Monitoring
Author(s) -
Brian McNabb,
Eric Vittinghoff,
Richard Eastell,
Ann V. Schwartz,
Douglas C. Bauer,
Kristine E. Ensrud,
Elizabeth BarrettConnor,
Dennis M. Black
Publication year - 2014
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2014-1193
Subject(s) - discontinuation , medicine , bone mineral , context (archaeology) , placebo , physical therapy , osteoporosis , paleontology , alternative medicine , pathology , biology
Women stopping alendronate are commonly monitored with serial bone mineral density (BMD) measurements, yet no information exists on how frequently or for whom these measurements should be performed.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom